- Care provider
- Ro
- Medication
- Wegovy injection; confirm presentation
- Membership
- $39 first month; then $149 monthly or prepaid terms
- Medication cost
- Additional; dose and program dependent
Specify injection when comparing Wegovy
Ro offers access to Wegovy within its branded medication menu. This review concerns the injection, rather than the oral tablet also carrying the Wegovy name. Current labeling includes more than one injectable dose and presentation.[source][source]
Ask which product and dose are being quoted. A search result that says Wegovy without its format can combine offers that are not directly comparable.
The head-to-head comparison is dose-specific
SURMOUNT-5 studied weekly injected semaglutide at a maximum tolerated 1.7 or 2.4 mg. It did not compare the newer 7.2 mg Wegovy HD regimen, oral Wegovy or the performance of Ro as a care provider.[source]
That limitation belongs beside the result. A trial of one regimen cannot settle every current product comparison.
Add care to the medication quote
Ro advertises a $39 initial membership month, a $149 ongoing monthly plan and lower monthly equivalents with prepayment. The medicine costs extra, with cash offers varying by product, dose and program.[source]
Get the complete initial and continuing charges. A prepayment discount may reduce the equivalent monthly fee while increasing the upfront commitment.
Use the current formulation-specific information
Wegovy labeling contains important contraindications and warnings, including the thyroid C-cell tumor boxed warning, gastrointestinal risks and precautions involving other medicines. Review it with the prescribing clinician; this article is not a complete safety guide.[source]
The current label, medical history and practical ability to continue treatment matter alongside a trial average.
A branded option with a separate service fee
This route is relevant for readers who want online care around an approved semaglutide injection. Compare it with another branded access pathway using the same dose and format, then evaluate what the membership contributes.
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Each source has its own last-checked date below.
- Ro: weight-loss careProvider care model and current medication menu · Checked October 8, 2026
- Wegovy prescribing informationManufacturer labeling; formulation-specific directions and safety information · Checked October 8, 2026
- Aronne et al., NEJM 2025: tirzepatide compared with semaglutide for obesityPrimary randomized trial abstract; SURMOUNT-5, 751 adults without diabetes, 72 weeks; funded by Eli Lilly · Checked October 8, 2026
- Ro: membership and medication pricingSeparate charges, prepayment periods and dose-specific offers · Checked October 8, 2026